Spantide II

• CAT Number: M113224
• CAS Number: 129176-97-2
• Molecular Formula: C86H104Cl2N18O13
• Molecular Weight: 1668.76
• Purity: ≥95%
• Synonyms: (2S)-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-1-oxohexan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]-2-[[(2R)-2-[[(2S)-1-[(2S)-2-[[(2S)-1-[(2R)-2-amino-6-(pyridine-3-carbonylamino)hexanoyl]pyrrolidine-2-carbonyl]amino]-3-pyridin-3-ylpropanoyl]pyrrolidine-2-carbonyl]amino]-3-(3,4-dichlorophenyl)propanoyl]amino]butanediamide
• InChI: InChI=1S/C86H104Cl2N18O13/c1-4-5-26-64(75(91)108)97-77(110)65(38-50(2)3)98-80(113)68(43-55-48-95-62-27-11-9-23-57(55)62)100-78(111)66(40-51-19-7-6-8-20-51)99-81(114)69(44-56-49-96-63-28-12-10-24-58(56)63)101-82(115)70(45-74(90)107)102-79(112)67(41-52-31-32-59(87)60(88)39-52)103-83(116)73-30-18-37-106(73)86(119)71(42-53-21-15-33-92-46-53)104-84(117)72-29-17-36-105(72)85(118)61(89)25-13-14-35-94-76(109)54-22-16-34-93-47-54/h6-12,15-16,19-24,27-28,31-34,39,46-50,61,64-73,95-96H,4-5,13-14,17-18,25-26,29-30,35-38,40-45,89H2,1-3H3,(H2,90,107)(H2,91,108)(H,94,109)(H,97,110)(H,98,113)(H,99,114)(H,100,111)(H,101,115)(H,102,112)(H,103,116)(H,104,117)/t61-,64+,65+,66+,67-,68-,69-,70+,71+,72+,73+/m1/s1
• InChIKey: VJPWTVLSHIDVRH-XCHUDMFJSA-N
• SMILES: CCCCC(C(=O)N)NC(=O)C(CC(C)C)NC(=O)C(CC1=CNC2=CC=CC=C21)NC(=O)C(CC3=CC=CC=C3)NC(=O)C(CC4=CNC5=CC=CC=C54)NC(=O)C(CC(=O)N)NC(=O)C(CC6=CC(=C(C=C6)Cl)Cl)NC(=O)C7CCCN7C(=O)C(CC8=CN=CC=C8)NC(=O)C9CCCN9C(=O)C(CCCCNC(=O)C1=CN=CC=C1)N

Spantide II (Cat No.: M113224) is a synthetic peptide and potent antagonist of the neurokinin-1 (NK1) receptor, which binds substance P, a neuropeptide involved in pain transmission, inflammation, and immune responses. By blocking NK1 receptor activation, Spantide II inhibits substance P-mediated signaling, reducing neurogenic inflammation and related symptoms. It has been studied for its therapeutic potential in conditions such as allergic rhinitis, dermatitis, and chronic inflammatory diseases. Spantide II is also used in research to explore neuropeptide signaling and receptor-specific inflammatory pathways.

Reference

[1]. Xu XJ, et al. Spantide II, a novel tachykinin antagonist, and galanin inhibit plasma extravasation induced by antidromic C-fiber stimulation in rat hindpaw. Neuroscience. 1991;42(3):731-7.
[Content Brief]

[2]. Kikwai L, et al. In vitro and in vivo evaluation of topical formulations of spantide II. AAPS PharmSciTech. 2005 Oct 31;6(4):E565-72.
[Content Brief]

[3]. Babu RJ, et al. Percutaneous absorption and anti-inflammatory effect of a substance P receptor antagonist: spantide II. Pharm Res. 2004 Jan;21(1):108-13.
[Content Brief]